# Gut Microbiota in Liver Cancer (Treated With TKIs In Combination With ICIs)

> **NCT06563934** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Xu Yong, MD** · enrollment: 70 (estimated)

## Conditions studied

- Liver Cancer

## Interventions

- **BIOLOGICAL:** Oral enterobacterium capsules
- **DRUG:** Lenvatinib + PD-1 monoclonal antibody
- **BIOLOGICAL:** Oral enterobacterium capsules placebo

## Key facts

- **NCT ID:** NCT06563934
- **Lead sponsor:** Xu Yong, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08-30
- **Primary completion:** 2026-05-20
- **Final completion:** 2026-11-20
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2024-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06563934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06563934, "Gut Microbiota in Liver Cancer (Treated With TKIs In Combination With ICIs)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06563934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*